It has been an eventful quarter for WntResearch that develops the drug candidate Foxy-5 for the treatment of colon cancer. The company is currently conducting the phase IIb study NeoFox from which the company recently announced promising findings, causing a rally in the stock. The company’s CEO Pernilla Sandwall attended BioStock Investor Meeting and told us more about both the company and the new findings.
Watch WntResearch’s CEO Pernilla Sandwall present the company below:The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.